South Korea-based Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has unveiled ExellenS TM – an optimised manufacturing framework applied across the company's biomanufacturing network.
Developed through Samsung Biologics' cumulative expertise in plant design, digitalisation, and operational excellence, ExellenSTM standardises equipment, processes, and functional specifications to ensure that every facility operates with the same precision. The framework delivers high-quality, predictable outcomes at speed, empowering clients with faster tech transfers, accelerated approvals, and seamless scaling.
ExellenSTM builds on the company's four pillars of excellence in client satisfaction, operations, quality, and people expertise to consistently maintain its manufacturing competitiveness as a pure-play global CDMO. By embedding standardisation, simplification, and scalability into every facility, Samsung Biologics is enabling clients to bring life-saving therapies to patients faster and with greater flexibility.
ExellenS™ integrates Functional Design Specifications (FDS) across all plants, replicating standardized bioreactor configurations and automation systems while allowing tailored improvements for manufacturing execution systems (MES) and continuous innovation. With a proven track record and deep know-how, Samsung Biologics has implemented a unified design model that delivers consistent results while minimising risks.
It enhances supply chain continuity by enabling dual-sourcing and multi-plant production. It also integrates unified digital platforms to help clients address challenges with unmatched scale, agility, and resilience. Minimised variability between plants, replicated processes, and universal equipment allow for rapid technology transfers and seamless scale-up, while integrated IT systems ensure compliance and audit readiness.
Samsung Biologics currently offers a total manufacturing capacity of 784,000 liters across five plants. Through 2032, the company plans to add capacity at Bio Campus II, home to its latest Plant 5 that became operational this April. The company also has a dedicated facility for the development and manufacturing of antibody-drug conjugates (ADCs) and global offices to serve clients worldwide.
